Key Points
- Insider purchase: Director Bruce Hiscock bought 66 shares of Bioventix on April 27 at an average price of GBX 1,679 per share, a total of £1,108.14.
- Shares trade around GBX 1,650 with a market cap of £86.21m and a P/E of 11.74; the 50-day MA (GBX 1,602.69) sits below the 200-day MA (GBX 1,818.29), and the 1‑year range is GBX 1,300–3,020.
- Bioventix, which supplies sheep monoclonal antibodies for diagnostics, reported strong profitability (Q EPS GBX 69.38, net margin 59.30%, ROE 65.83%) and analysts forecast about 166.31 EPS for the current fiscal year.
Bioventix PLC (LON:BVXP - Get Free Report) insider Bruce Hiscock purchased 66 shares of the company's stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average price of GBX 1,679 per share, for a total transaction of £1,108.14.
Bioventix Price Performance
Shares of Bioventix stock opened at GBX 1,650 on Wednesday. The stock has a market cap of £86.21 million, a price-to-earnings ratio of 11.74 and a beta of 0.48. The firm's 50-day moving average is GBX 1,602.69 and its 200 day moving average is GBX 1,818.29. Bioventix PLC has a 1 year low of GBX 1,300 and a 1 year high of GBX 3,020.
Bioventix (LON:BVXP - Get Free Report) last posted its earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share (EPS) for the quarter. The business had revenue of GBX 615.88 billion for the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. On average, equities analysts expect that Bioventix PLC will post 166.3066955 EPS for the current fiscal year.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
